AB Corporate Bond ETF
EYEGDividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 5, 2026 | $0.19 | 2025-12-31 | 2025-12-31 |
| December 4, 2025 | $0.14 | 2025-12-01 | 2025-12-01 |
| November 6, 2025 | $0.14 | 2025-11-03 | 2025-11-03 |
| October 6, 2025 | $0.14 | 2025-10-01 | 2025-10-01 |
| September 5, 2025 | $0.14 | 2025-09-02 | 2025-09-02 |
Dividends Summary
- Consistent Payer: AB Corporate Bond ETF has rewarded shareholders with 25 dividend payments over the past 2 years.
- Total Returned Value: Investors who held EYEG shares during this period received a total of $3.98 per share in dividend income.
- Latest Payout: The most recent dividend of $0.19/share was paid 18 days ago, on January 5, 2026.
- Yield & Schedule: EYEG currently pays dividends monthly with an annual yield of 4.93%.
- Dividend Growth: Since 2024, the dividend payout has grown by 103.0%, from $0.09 to $0.19.
Company News
This article provides a beginner's guide to investing in different types of bonds, including municipal, corporate, government, and foreign bonds. It discusses factors to consider when choosing bonds, such as risk tolerance, investment goals, and tax implications. The article also outlines several bond investment strategies for beginners.
Investing in penny stocks in 2021? Check these three out for next months watchlist The post Best Penny Stocks to Buy Right Now? 3 to Watch in October appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny stocks that may be worth watching right now. The post Penny Stocks For Your Biotech Watch List In September 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Biotech Penny Stocks Surge As Sector Reverses Course The post 4 Penny Stocks To Buy According To Analysts & Price Targets Up To 507% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
WALTHAM, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company developing and commercializing products for treating ophthalmic diseases, today announced that EyeGate’s President and Chief Executive Officer, Brian M. Strem...
